Login to Your Account



Preparing To File Satraplatin NDA, GPC Brings In $44M

By Jennifer Boggs


Thursday, January 25, 2007
Four months after GPC Biotech AG's satraplatin met its endpoint in a pivotal prostate cancer study, the company pulled in €33.6 million (US$43.7 million) to pave the way for the compound's anticipated commercialization. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription